Literature DB >> 23464989

Fibroblasts from methotrexate-sensitive mice accumulate methotrexate polyglutamates but those from methotrexate-resistant mice do not.

Xin You1, Adrienne Williams, Thierry Dervieux, Wenjie He, Bruce N Cronstein.   

Abstract

OBJECTIVES: We and others have previously demonstrated that methotrexate (MTX) mediates its anti-inflammatory effects through an increase in cellular release of adenosine. Consistent with this observation, there is no increase in adenosine from exudates of mouse strains resistant to MTX. Because intracellular MTX polyglutamates inhibit AICAR transformylase (ATIC) activity and thereby promote adenosine release we determined whether there is any difference in the capacity of cells from MTX-resistant mice to accumulate MTX polyglutamates.
METHODS: Dermal fibroblasts (DF) from BALBc, MTX-sensitive, and DBA/1J, MTX-resistant, mice were cultured in the presence or absence of MTX. Adenosine concentration in the supernatant and intracellular MTX polyglutamate (MTXPG1-5) concentrations were measured by liquid chromatography. ATIC activity in DF was monitored spectrophotometrically by the formation of formytetrahydrofolate.
RESULTS: MTX (1 μM) increased adenosine production by DF from BALBc sensitive-mice from 269±40 nM to 446±4 nM. No adenosine production was found in supernates of cultured DF from DBA/1J mice regardless of MTX treatment. Intracellular MTX polyglutamates (MTXPG2-4) were detected only in BALBc DFs, not in DBA/1J DF. Further investigation demonstrated that ATIC activity was inhibited following MTX treatment in DF from BALBc mice.
CONCLUSIONS: These data suggest that resistance to the anti-inflammatory effects of MTX could be due to diminished MTX polyglutamate accumulation resulting in diminished ATIC inhibition and adenosine accumulation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23464989      PMCID: PMC3844927     

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  10 in total

Review 1.  Polyglutamation of methotrexate. Is methotrexate a prodrug?

Authors:  B A Chabner; C J Allegra; G A Curt; N J Clendeninn; J Baram; S Koizumi; J C Drake; J Jolivet
Journal:  J Clin Invest       Date:  1985-09       Impact factor: 14.808

Review 2.  How does methotrexate suppress inflammation?

Authors:  B Cronstein
Journal:  Clin Exp Rheumatol       Date:  2010-10-28       Impact factor: 4.473

3.  An interaction between genetic factors and gender determines the magnitude of the inflammatory response in the mouse air pouch model of acute inflammation.

Authors:  David L Delano; M Carmen Montesinos; Peter D'Eustachio; Tim Wiltshire; Bruce N Cronstein
Journal:  Inflammation       Date:  2005-02       Impact factor: 4.092

4.  Genetically based resistance to the antiinflammatory effects of methotrexate in the air-pouch model of acute inflammation.

Authors:  David L Delano; M Carmen Montesinos; Avani Desai; Tuere Wilder; Patricia Fernandez; Peter D'Eustachio; Tim Wiltshire; Bruce N Cronstein
Journal:  Arthritis Rheum       Date:  2005-08

Review 5.  Methotrexate--how does it really work?

Authors:  Edwin S L Chan; Bruce N Cronstein
Journal:  Nat Rev Rheumatol       Date:  2010-03       Impact factor: 20.543

6.  HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis.

Authors:  Thierry Dervieux; Diana Orentas Lein; John Marcelletti; Ken Pischel; Katie Smith; Michael Walsh; Russell Richerson
Journal:  Clin Chem       Date:  2003-10       Impact factor: 8.327

7.  Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates.

Authors:  C J Allegra; J C Drake; J Jolivet; B A Chabner
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

8.  The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation.

Authors:  B N Cronstein; D Naime; E Ostad
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

Review 9.  Adenosine receptors: therapeutic aspects for inflammatory and immune diseases.

Authors:  György Haskó; Joel Linden; Bruce Cronstein; Pál Pacher
Journal:  Nat Rev Drug Discov       Date:  2008-09       Impact factor: 84.694

10.  Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5'-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide.

Authors:  J E Baggott; W H Vaughn; B B Hudson
Journal:  Biochem J       Date:  1986-05-15       Impact factor: 3.857

  10 in total
  4 in total

1.  Low-dose methotrexate results in the selective accumulation of aminoimidazole carboxamide ribotide in an erythroblastoid cell line.

Authors:  Ryan S Funk; Leon van Haandel; Mara L Becker; J Steven Leeder
Journal:  J Pharmacol Exp Ther       Date:  2013-07-25       Impact factor: 4.030

2.  Methotrexate disposition, anti-folate activity and efficacy in the collagen-induced arthritis mouse model.

Authors:  Rakesh K Singh; Leon van Haandel; Paul Kiptoo; Mara L Becker; Teruna J Siahaan; Ryan S Funk
Journal:  Eur J Pharmacol       Date:  2019-04-02       Impact factor: 4.432

3.  Ticagrelor added to methotrexate improves rheumatoid arthritis disease severity.

Authors:  Michael S Garshick; Pamela B Rosenthal; Elliot Luttrell-Williams; Bruce N Cronstein; Jeffrey S Berger
Journal:  Rheumatology (Oxford)       Date:  2021-11-03       Impact factor: 7.580

4.  Identification and characterization of critical genes associated with tamoxifen resistance in breast cancer.

Authors:  Kai Zhang; Kuikui Jiang; Ruoxi Hong; Fei Xu; Wen Xia; Ge Qin; Kaping Lee; Qiufan Zheng; Qianyi Lu; Qinglian Zhai; Shusen Wang
Journal:  PeerJ       Date:  2020-12-04       Impact factor: 2.984

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.